FDA Approves NRx Pharmaceuticals’ Generic Ketamine Injection
Photo: TokenPost
The U.S. Food and Drug Administration (FDA) approved NRx Pharmaceuticals’ generic ketamine injection, a decision that may help ease U.S. supply constraints for ketamine used in pain treatment and anesthesia. NRx Pharmaceuticals shares rose more than 15% in premarket trading Friday, Oct. 30. Ketamine is used in pain treatment and anesthesia. The approval may help ease supply constraints for those uses in the United States. Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
